Orphan Drug Status Granted to Treatment for Relapsed DLBCL

Karyopharm Therapeutics Inc. has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for their lead drug candidate for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL).

Karyopharm Therapeutics is a self-described "clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases."

The drug in question is Selinexor (KPT-330). This is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor works by binding to the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus. This re-initiates and even amplifies their tumor suppressor function, which in turn is believed to lead to the selective induction of apoptosis (programmed cell death) in cancer cells.

So far, over 300 patients have been treated with Selinexor in Phase 1 and Phase 2 clinical trials in advanced hematologic malignancies and solid tumors.

"The granting of Orphan Drug Designation by the FDA for DLBCL is another significant milestone in the Selinexor development program," said Dr. Sharon Shacham, Founder, CSO and President of Karyopharm. "There are limited treatment options for patients with relapsed or refractory DLBCL, with no new agents approved for this indication over the past two decades. Many patients relapse after responding to multi-agent first-line therapy. The fundamental treatment of DLBCL has changed little in the past two decades, with no new or targeted agents approved for this indication.

"Accordingly, we are excited about the prospects for Selinexor's novel mechanism of action to potentially treat this patient population, either alone or in combination with other therapies."

Source: MarketWatch

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...